Paper42005455
Significance of SLC1A5 expression in head and neck squamous cell carcinoma: A bioinformatics and in-vitro analysis.
Kaarunya S and 3 others. J Oral Biol Craniofac Res, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Significance of SLC1A5 expression in head and neck squamous cell carcinoma: A bioinformatics and in-vitro analysis. Papers, record 42005455. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42005455
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Significance of SLC1A5 expression in head and neck squamous cell carcinoma: A bioinformatics and in-vitro analysis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29326164 | The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5). | J Biol Chem | 2018 | https://conductscience.org/library/papers/29326164 | PubMed |
| 2 | 33953707 | Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment. | Front Immunol | 2021 | https://conductscience.org/library/papers/33953707 | PubMed |
| 3 | 39223142 | The disruption of NEAT1-miR-125b-5p-SLC1A5 cascade defines the oncogenicity and differential immune profile in head and neck squamous cell carcinoma. | Cell Death Discov | 2024 | https://conductscience.org/library/papers/39223142 | PubMed |
| 4 | 31866442 | A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells. | Cell Metab | 2020 | https://conductscience.org/library/papers/31866442 | PubMed |
| 5 | 40362545 | The Possibility of Plasma Membrane Transporters as Drug Targets in Oral Cancers. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40362545 | PubMed |
| 6 | 38844930 | Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. | J Transl Med | 2024 | https://conductscience.org/library/papers/38844930 | PubMed |
| 7 | 36950604 | SLC1A5, unrelated to prognosis, was associated with CD8+ T-cell exclusion in the tumor microenvironment of squamous cell carcinoma. | Heliyon | 2023 | https://conductscience.org/library/papers/36950604 | PubMed |
| 8 | 41184297 | Targeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var. | Nat Commun | 2025 | https://conductscience.org/library/papers/41184297 | PubMed |
| 9 | 34171602 | Comprehensive molecular and clinical characterization of SLC1A5 in human cancers. | Pathol Res Pract | 2021 | https://conductscience.org/library/papers/34171602 | PubMed |
| 10 | 14557543 | Genomewide screening for fusogenic human endogenous retrovirus envelopes identifies syncytin 2, a gene conserved on primate evolution. | Proc Natl Acad Sci U S A | 2003 | https://conductscience.org/library/papers/14557543 | PubMed |
| 11 | 39335197 | The Solute Carrier (SLC) Transporter Superfamily as Therapeutic Targets for the Treatment of Head and Neck Squamous Cell Carcinoma. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39335197 | PubMed |
| 12 | 37752146 | Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37752146 | PubMed |
| 13 | 38000245 | Prediction and related genes of cancer distant metastasis based on deep learning. | Comput Biol Med | 2024 | https://conductscience.org/library/papers/38000245 | PubMed |
| 14 | 25821004 | Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer. | Int J Cancer | 2015 | https://conductscience.org/library/papers/25821004 | PubMed |
| 15 | 35487063 | Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma. | Biochem Biophys Res Commun | 2022 | https://conductscience.org/library/papers/35487063 | PubMed |
| 16 | 35794606 | Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment. | J Transl Med | 2022 | https://conductscience.org/library/papers/35794606 | PubMed |
| 17 | 39660050 | Crosstalk between metabolic and epigenetic modifications during cell carcinogenesis. | iScience | 2024 | https://conductscience.org/library/papers/39660050 | PubMed |
| 18 | 40312304 | Integrating transcriptomic and metabolomic analyses to characterize the potential function of SLC1A5 in thyroid cancer. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40312304 | PubMed |
| 19 | 41264384 | Prognostic Factors in Patients With Locally Advanced Hypopharyngeal Squamous Cell Carcinoma After Radical Radiotherapy/Chemoradiotherapy. | Cancer Med | 2025 | https://conductscience.org/library/papers/41264384 | PubMed |
| 20 | 38534987 | Targeting Solute Carrier Transporters (SLCs) as a Therapeutic Target in Different Cancers. | Diseases | 2024 | https://conductscience.org/library/papers/38534987 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42005455
GET https://conductscience.org/api/papers/v1/42005455/references?page=2